Erythrocyte Aggregation In Patients Research Articles

Blood rheology and systemic oxidative status in patients with acromegaly

Background Cardiovascular system is known to be affected in acromegaly. However, it was not reported to date if hemorheology was also altered and there is limited data regarding systemic oxidative status in patients with acromegaly. Objective To investigate alterations in hemorheology and systemic oxidative stress in patients with acromegaly. Methods The study comprised 19 active (AA) and 15 controlled (CA) acromegaly patients (n = 34, mean age 48.85 ± 1.69 years) and 29 controls (mean age 52.83 ± 1.37 years). Erythrocyte aggregation index (AI), aggregation half time (t½), amplitude (Amp) and erythrocyte elongation index (EI) were determined by an ektacytometer. Commercial kits were used for measuring serum total oxidant status (TOS) and total antioxidant status (TAS), and oxidative stress index (OSI) was calculated. Results There were statistically significant differences regarding EI at shear stresses of 16.87 ve 30.00 Pa (p = 0.034, p = 0.0001, respectively) and AI (p = 0.050, p = 0.035, respectively) values among the control, AA and CA groups. Decrement of t½ was in line with increment of AI and indicated increased erythrocyte aggregation. Serum TOS, TAS and OSI values were similar between the control, AA and CA groups (p > 0.05). Conclusions This pilot study demonstrated reduced erythrocyte deformability and increased erythrocyte aggregation in patients with AA and CA.

Finding possible diagnostic markers for differentiating benign and malignant thyroid tumors on example investigate of rheological properties1.

The functioning of the thyroid gland is a multi-component process that in some conditions may undergo alterations. The thyroid gland is part of the endocrine system that produces the iodine-containing hormones thyroxine and triiodothyronine. Thyroid hormones, control metabolism and energy, growth processes, maturation of tissues and organs, regulation of blood flow, and, therefore, providing vital functions of the body. The role of thyroid hormones in the regulation of blood flow is determined by the intensity of their production and the quantity in the blood. Presumably, in case of oncological and non-oncological diseases of the thyroid gland, the fluidity of the blood, which depends on the rheological properties, will be different. Our aim was investigating rheological characteristics for studying of changes of rheology in patients with thyrotoxicosis, with benign tumor pathology of the thyroid gland, with thyroid cancer and finding possible diagnostic markers for differentiating benign and malignant thyroid tumors. In this regard, we examined, using modern methods accepted in clinical practice, a standard list of recommended diagnostic tests in the group of patients (thyrotoxicosis: n = 25; benign tumor: n = 47), thyroid cancer: n = 35) and control group (n = 15), and with new original methods, parameters that describe the rheological properties of the blood, such as blood rheological index, volume, thickness, surface area of erythrocytes, erythrocyte aggregation index, deformation index, plasma viscosity, hematocrits. Against the background of relative changes in the studied values, it is necessary to pay attention to the fact that erythrocyte aggregation in patients with a benign form and control, as well as in patients with a malignant form and control, differ significantly from each other, in addition, there is a significant difference between aggregation in the group of patients with benign and control aggregation. malignant forms of the disease. It is significant that aggregability differs in patients with thyrotoxicosis and in controls. This indicates that erythrocyte aggregation is particularly informative. The blood rheological index most clearly demonstrated the difference between benign and malignant forms of the disease. Significantly changed compared to control in various forms of thyroid diseases. Additional diagnostic markers for differentiating benign and malignant thyroid tumors may be consideredeerythrocyte aggregation index and blood rheological index.

Hemorheological study on erythrocyte aggregation in patients with type 2 diabetes mellitus without cholesterol and with hyper cholesterol

BackgroundThe aggregation of erythrocytes has been studied in many pathological conditions like diabetes mellitus, malaria, jaundice, hyper cholesterol, etc. Different types of erythrocyte aggregation occur in different pathological conditions. Enhanced aggregation was found in pathological conditions compared to control subjects. ObjectiveThis research aims to study the aggregation of erythrocytes in type 2 diabetes mellitus subjects without cholesterol and with cholesterol and to compare such subjects with healthy subjects. MethodsAggregation of erythrocytes was determined using an online erythrocyte aggregometer based on sequential analysis of transmitted laser light intensity after passing through the erythrocyte suspension in plasma. The aggregation mechanism was determined in terms of several aggregation parameters such as aggregation size index (ASI), aggregation sedimentation time index (ASTI), and the total number of fluctuations (TNF) of erythrocyte aggregates. These parameters were used to describe the dynamic nature of the aggregation process under gravitation quantitatively. There were a total of 45 subjects (control subjects (n = 10)), diabetes with normal cholesterol (n = 24), and diabetes with hyper cholesterol (n = 21) in this study. ResultsThe aggregation parameter total number of fluctuations (TNF) was 1634 ± 397 in normal subjects, 1539 ± 197 in group 1, and 1096 ± 180 in group 2. The aggregation sedimentation time index (ASTI, Fig. 2) indicates the time taken by the aggregates to sediment (28–32 min for normal, 24–28 min for group 1, and 16–20 min for group 2 subjects). The aggregation parameters decreased in diabetes with normal cholesterol and were significantly decreased in diabetes with hyper cholesterol compared to controls. The results show that in patients with diabetes with normal cholesterol, the aggregation of erythrocytes is increased and in patients with diabetes with hyper cholesterol, the aggregation increased significantly. ConclusionsThe significant increase in aggregation in diabetes with hypercholesterol may increase the microcirculatory complications compared to diabetes with normal cholesterol.

Increased erythrocyte aggregation in patients with primary open angle glaucoma

BackgroundThe rationale of this study is to determine alterations in blood rheology (erythrocyte aggregation and deformability) and relationship between structural measurements obtained from optical coherence tomography (OCT) in different stages of primary open angle glaucoma (POAG).MethodsThis prospective controlled study comprised 23 POAG patients (glaucoma group) and 23 age‐ and sex‐matched healthy subjects (control group). Elongation index (EI), which is the indicator of erythrocyte deformability and erythrocyte aggregation was measured using an ektacytometer. Optic nerve head (ONH) morphology and peripapillary retinal nerve fibre layer (RNFL) thickness were evaluated using a spectral domain (SD) OCT.ResultsThere were no significant differences between the groups regarding the elongation index values (p > 0.05). On the other hand, erythrocyte aggregation amplitude (AMP) and mean corpuscular haemoglobin concentration (MCHC) were significantly higher in the glaucoma group than in the control group (p = 0.015, p = 0.003 respectively). A significant correlation was also found between the elongation index and retinal nerve fibre layer (average and superior) thickness (p < 0.05) in patients with late glaucoma.ConclusionsIn patients with POAG, erythrocyte aggregation appears to be higher. It can be speculated that higher erythrocyte aggregation and deformability may be involved in the pathogenesis of glaucoma by affecting microperfusion of the optic nerve head and retina. Modification of rheological parameters in patients with glaucoma may be considered as an adjuvant future therapy in glaucoma management, whereas further studies in larger groups are needed.

高コレステロール血症患者における pravastatin の赤血球 aggregability に対する影響

高コレステロール血症患者における pravastatin の赤血球 aggregability に対する影響

Erythrocyte aggregation in patients with systemic lupus erythematosus

Systemic Lupus Erythematosus (SLE) is an autoimmune, chronic inflammatory, non-organ specific disease. SLE patients present a high prevalence of thrombotic and arteriosclerotic disease. The aim of the present work was to study the erythrocyte aggregation kinetics, and the effect of plasma factors, namely, immunoglobulin and fibrinogen concentration, as well as cell factors such as deformability and erythrocyte membrane lipid fluidity on the erythrocyte aggregation, in SLE patients and healthy controls. The results show that SLE patients red blood cells aggregate at higher rate and the aggregates size are also greater than controls due to an increase of immunoglobulin and plasma fibrinogen. The negative correlation between aggregation parameters and rigidity index could point out that the altered deformability diminishes the erythrocyte aggregation. Correlation between rigidity index and anisotropy suggests that the decrease of membrane lipid fluidity might be a cause of deformability decrease. The erythrocyte aggregation increase in these patients could induce a decreased flow that might contribute to the thromboembolic process present in SLE patients.

Inflammation-Related Erythrocyte Aggregation in Patients with Inflammatory Bowel Disease

Chronic inflammation is associated with increased erythrocyte adhesiveness/aggregation. This might have deleterious effects on the microcirculatory flow and tissue oxygenation. We aimed to determine the degree of erythrocyte adhesiveness/aggregation in the peripheral blood of individuals with inflammatory bowel disease (IBD). Fifty-two patients (24 women and 28 men) with ulcerative colitis (UC) at a mean age of 44.0+/-16.8 years and 96 patients (44 women and 52 men) with Crohn's disease (CD) at a mean age of 38.0+/-15.5 years, with various degrees of disease activity, were matched to normal controls. A simple slide test and image analysis were used to determine the degree of erythrocyte adhesiveness/aggregation. CD activity index (CDAI) was determined in patients with CD, while clinical colitis activity index was applied for patients with UC. A significant (P < 0.0005) increment in the degree of erythrocyte adhesiveness/aggregation was noted in both groups of IBD patients compared with matched control groups. This increment was evident even in individuals with a low index of disease activity and during remission. The highly significant correlation with the concentrations of fibrinogen suggests that the degree of erythrocyte adhesiveness/aggregation is an inflammation-related phenomenon. An enhanced state of erythrocyte adhesiveness/aggregation was noted in the peripheral blood of patients with IBD. This might have a deleterious effect on intestinal microcirculatory flow and tissue oxygenation.

Combined leukocyte and erythrocyte aggregation in patients with acute myocardial infarction

Objectives: To determine whether the increased aggregability of both white and red blood cells previously reported in acute myocardial infarction (aMI) correlates with each other. Design: Cross-sectional study comparing two groups of patients and a group of healthy controls. Setting: A tertiary university affiliated hospital (Intensive Cardiac Care Unit and Department of General Internal Medicine). Patients: Consecutive patients with aMI, patients with chest pain and no infarction, and healthy controls. Measurements and results: We adapted a simple slide test and image analysis to reveal the state of both leukocyte and erythrocyte adhesiveness/aggregation in the peripheral blood of patients with aMI. A significant ( P=0.0001) increment in the aggregation of both cellular populations was noted in 48 patients with aMI as opposed to the 141 patients with ischemic heart disease and no infarction and in 45 matched controls. In addition, a significant correlation was noted between the various variables of the leukocyte and erythrocyte adhesiveness/aggregation tests. Conclusions: The significant correlation between the aggregability of white and red blood cells in patients with aMI is suggestive of there being a commonly shared adhesive protein(s). The prompt identification of patients with increased aggregation might have clinical and therapeutic implications.

Contribution of the -455G/A Polymorphism at the β-fibrinogen Gene to Erythrocyte Aggregation in Patients with Coronary Artery Disease

A high level of red blood cell (RBC) aggregation has been consistently found in patients with coronary artery disease (CAD) in case-control studies. Plasma fibrinogen has been shown to promote RBC aggregability. The purpose of this study was to investigate the influence of the genetic variability of the beta-fibrinogen gene on RBC aggregation in patients with CAD. The genotype of the beta-fibrinogen gene locus was determined by polymerase chain reaction using the restriction enzyme HaeIII for a G to A substitution at position -455 upstream from the transcriptional start site in 135 French Canadians with premature CAD (age: 51+/-7 years). Indices measuring the RBC aggregation kinetics (S10) and shear resistance of the aggregates (gammaS) were obtained by laser reflectometry. Patients were separated into groups by using the medians of S10 and gammaS. Using chi2 analyses, the distribution of the -455GG, -455GA, and -455AA genotypes in the groups with high levels of S10 (0.43, 0.49, and 0.08) and gammaS (0.45, 0.49, and 0.06) were found to be significantly distinct from those in the groups with low levels of S10 (0.67, 0.27, and 0.06; p<0.05) and gammaS (0.70, 0.23, and 0.07; p<0.01). High levels of RBC aggregation were closely associated with the rare -455A allele. Multivariate linear regression analyses showed that S10 was positively correlated with the linear combination of the fibrinogen concentration, age, and the -455G/A genotype (adjusted r = 0.63, p<0.0001). Fibrinogen and age were positive determinants, and HDL-cholesterol was a negative predictor of gammaS (adjusted r = 0.51, p<0.0001). These findings support the hypothesis that RBC hyperaggregation in premature CAD may be associated with the beta-fibrinogen -455G/A polymorphism. This association may be explained by a change in the concentration and/or the functional properties of the fibrinogen protein.

Effect of ibudilast on erythrocyte aggregability in patients with cerebral infarction

Effect of ibudilast on erythrocyte aggregability in patients with cerebral infarction

Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction

We examined the effect of aspirin on the enhanced erythrocyte aggregability in 19 patients with cerebral infarction during the chronic phase. Aspirin (81 mg/day) was administered for 8 weeks. The rate of erythrocyte aggregation (aggregability) was measured using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205–H1210, 1986) before, and at 4 and 8 weeks after initiation of the aspirin administration. Concomitant measurements were made of certain blood factors such as the hematocrit, albumin-globulin ( A G ) ratio and fibrinogen concentration. The erythrocyte aggregation rates before, and at 4 and 8 weeks were 0.154 ± 0.019/s, 0.144 ± 0.020/s, and 0.143 ± 0.020/s, respectively. The erythrocyte aggregation rates at 4 and 8 weeks were significantly ( P < 0.05, Bonferroni's modified t-test) lower than that before aspirin administration. Although the hematocrit value and A G ratio were not changed at 4 and 8 weeks after the initiation of aspirin, the concentration of fibrinogen were significantly ( P < 0.05) reduced at 4 weeks. The above results suggest that aspirin can improve the enhanced erythrocyte aggregability in patients with cerebral infarction during the chronic phase.

Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction

We examined the effect of aspirin on the enhanced erythrocyte aggregability in 19 patients with cerebral infarction during the chronic phase. Aspirin (81 mg/day) was administered for 8 weeks. The rate of erythrocyte aggregation (aggregability) was measured using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205–H1210, 1986) before, and at 4 and 8 weeks after initiation of the aspirin administration. Concomitant measurements were made of certain blood factors such as the hematocrit, albumin-globulin () ratio and fibrinogen concentration. The erythrocyte aggregation rates before, and at 4 and 8 weeks were 0.154 ± 0.019/s, 0.144 ± 0.020/s, and 0.143 ± 0.020/s, respectively. The erythrocyte aggregation rates at 4 and 8 weeks were significantly (P < 0.05, Bonferroni's modified t-test) lower than that before aspirin administration. Although the hematocrit value and ratio were not changed at 4 and 8 weeks after the initiation of aspirin, the concentration of fibrinogen were significantly (P < 0.05) reduced at 4 weeks. The above results suggest that aspirin can improve the enhanced erythrocyte aggregability in patients with cerebral infarction during the chronic phase.

Erythrocyte aggregability in patients with coronary heart disease

Erythrocyte aggregation (EA) rates were measured at stasis (M) and at 3 sec- 1 (Ml) in four groups: healthy controls (HC) and three groups of coronary heart disease (CHD); stable angina pectoris (SAP), unstable angina pectoris (USAP) and post myocardial infarction (PostMI) patients. All CHD patients had similar risk factors. EA values were significantly higher. at M and M1 in USAP and PostMI groups than HC and SAP (p O.05). Since EA is higher in more severe forms of CHD (USAP and PostMI) and atherosclerosis is more common in men than women before menopause, it is possible that EA might play a role in the development of especially severe forms of CHD.

Effect of ibudilast on erythrocyte aggregability in patients with cerebral infarction

Effect of ibudilast on erythrocyte aggregability in patients with cerebral infarction

F188. Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction

F188. Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction

Influence of Sodium Fluorescein on Erythrocyte Aggregation in Patients with Cerebral Microangiopathy

Influence of Sodium Fluorescein on Erythrocyte Aggregation in Patients with Cerebral Microangiopathy

Effect of single intravenous administration of batroxobin on erythrocyte aggregability in patients with acute-stage cerebral infarction

(Received 27.09.1994; accepted 24.11.1994) We examined the effect of defibrinogenation with batroxobin on the erythrocyte aggregability (RBC-A) in 16 patients with cerebral infarction during the acute phase (less than 72 hours after onset). Eight patients received a single intravenous administration of 10 units of batroxobin (BU), while the other 8 patients received 5 BU. The RBC-A was examined using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205H1210, 1986) with concomitant measurement of the hematocrit, albumin:globulin ratio and concentration of fibrinogen. The RBC-A values before, and at 1,2, and 7 days after 10 BU administration were 0.154±0.017/s, 0.117 ±0.029/s (76% of the value before the administration, P<O.Ol), 0.105±0.029/s (68%, P<O.Ol), and 0.124±0.015/s (81 %, P<O.Ol), respectively. The fibrinogen concentrations before, and at 1,2, and 7 days after the batroxobin were 364±81 mg/dl, 150±35 mg/dl (41 %, P<O.Ol), 129±35 mg/dl (35%, P<O.01), and 211±42 mg/dl (58%, P<O.Ol), respectively; On the other hand, the RBC-A values before, and at 1, 2, and 7 days after 5 BU administration were 0.143±0.021/s, 0.131±0.036/s, 0.130±0.028/s, and 0.141±0.029/s, respectively. The fibrinogen concentrations before, and at 1,2, and 7 days after the batroxobin were 318±57 mg/dl, 255±60 mg/dl (80%, P<O.Ol), 259±68 mg/dl (81 %, P<O.Ol), and 319±87 mg/dl, respectively. We conClude that a single intravenous administration of batroxobin at 10 BU reduced the RBC-A in patients with cerebral infarction during the acute phase in accordance with a decrease in the fibrinogen level. The effect appeared to last for more than 7 days.

Platelet activation and erythrocyte aggregability in patients with cerebral infarction

Platelet activation and erythrocyte aggregability in patients with cerebral infarction

Elevated Erythrocyte Aggregation in Patients with Central Retinal Vein Occlusion and without Conventional Risk Factors

Retinal venous circulation is characterized by the combination of a low flow state and a high vascular resistance, which would make it particularly dependent on blood viscosity. Erythrocyte aggregation is the chief determinant of blood viscosity at low shear rates. Recent studies have demonstrated increased erythrocyte aggregation in many systemic vascular disorders and also in retinal vein occlusion. To assess the possible role of abnormal hemorheologic findings in the pathogenesis of central retinal vein occlusion (CRVO), the authors retrospectively studied erythrocyte aggregation and hematocrit and fibrinogen levels in 33 patients with CRVO and without any known risk factors (diabetes, hypertension, smoking, hyperlipidemia, cardiovascular disease, glaucoma). Erythrocyte aggregation was assessed with a light back-scattering method. Results were compared with those of a group of 33 age- and sex-matched controls. Eleven (33%) of the 33 patients with CRVO had abnormal hemorheologic findings. Erythrocyte aggregation was highly significantly increased in the CRVO group when compared with the control group (P < 0.0001), as was the hematocrit level (P < 0.05). In addition, the proportion of patients with abnormal blood rheologic tests was greater (50%) in the subgroup of patients who initially had nonischemic CRVO that worsened into an ischemic CRVO during the follow-up. These data suggest that abnormal hemorheologic findings could affect the pathogenesis of CRVO, and perhaps be predictive of an aggravation. The latter hypothesis needs to be confirmed in a larger, prospective study.

Ticlopidine improves the enhanced erythrocyte aggregability in patients with cerebral infarction.

We examined the effect of ticlopidine hydrochloride on the enhanced erythrocyte aggregability in 14 patients with cerebral infarction during the chronic phase (over 1 month after onset). Ticlopidine (100 mg BID) was administered for 8 weeks. We measured the rate of erythrocyte aggregation (aggregability), using the whole-blood erythrocyte aggregometer that we developed, before and at 4 and 8 weeks after the initiation of ticlopidine administration. Concomitant measurements were made of such blood factors as the hematocrit, albumin-globulin ratio, and fibrinogen concentration. The erythrocyte aggregation rates before and at 4 and 8 weeks after were 0.147 +/- 0.017/s, 0.138 +/- 0.019/s, and 0.133 +/- 0.017/s, respectively. The erythrocyte aggregation rates at 4 and 8 weeks were significantly lower (P < .05 by Bonferroni's modified t test) than those before ticlopidine administration. At 4 and 8 weeks after the initiation of ticlopidine treatment, the hematocrit value and concentration of fibrinogen were also significantly (P < .05) reduced. Our results suggest that ticlopidine can improve the enhanced erythrocyte aggregability in patients with cerebral infarction during the chronic phase.